What it's for (Indications)
- Tamoxifen is a selective estrogen receptor modulator (SERM) indicated for the treatment of various forms of breast cancer and for breast cancer prevention.
- Specifically, its indications include: 1.
- Treatment of estrogen receptor-positive (ER+) metastatic breast cancer in women and men.
- 2.
- Adjuvant treatment of ER+ early-stage breast cancer in women and men following primary therapy.
- 3.
- Reduction in the incidence of contralateral breast cancer in patients who have received adjuvant tamoxifen therapy for ER+ breast cancer.
- 4.
- Treatment of ductal carcinoma in situ (DCIS) in women following breast surgery and radiation to reduce the risk of invasive breast cancer.
- 5.
- Reduction in the incidence of invasive breast cancer in women at high risk for the disease.
- The determination of ER positivity is critical for optimal patient selection, as tamoxifen's efficacy is largely dependent on the presence of these receptors.
- Treatment duration often extends for several years, typically up to five years for adjuvant and preventive settings, based on clinical trials demonstrating significant benefit in disease-free survival and overall survival.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of tamoxifen varies depending on the indication. For the treatment of metastatic breast cancer or adjuvant treatment of early-stage breast cancer, the usual dose is 20 mg administered orally once daily. Some clinical studies have utilized a dosage of 10 mg twice daily, achieving similar efficacy. For the treatment of ductal carcinoma in situ (DCIS) and for reducing the incidence of invasive breast cancer in high-risk women, the recommended dose is 20 mg orally once daily for a duration of five years. Patients should be advised to take tamoxifen at approximately the same time each day. It can be taken with or without food. In cases where a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next dose, in which case the missed dose should be skipped to avoid taking a double dose. Adherence to the prescribed regimen is crucial for maximizing therapeutic benefit and minimizing the risk of recurrence or disease progression. |
Safety & Warnings
Common Side Effects
- Tamoxifen can cause a range of side effects, varying in severity and frequency.
- Common adverse effects, often related to its anti-estrogenic activity, include hot flashes, nausea, vomiting, fatigue, vaginal discharge, vaginal bleeding, irregular menstrual periods, weight gain, fluid retention, and mood changes.
- Less common but serious side effects warranting immediate medical attention include: **Thromboembolic events:** deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke.
- **Uterine effects:** endometrial cancer, uterine sarcoma, uterine fibroids, and endometrial hyperplasia.
- **Ocular effects:** cataracts, retinopathy, and visual disturbances.
- **Liver effects:** elevation of liver enzymes, fatty liver, cholestasis, and, rarely, hepatic necrosis.
- **Skin reactions:** rash, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
- Other reported side effects include bone pain (especially in patients with bone metastases), tumor flare (transient increase in bone or soft tissue pain and erythema at tumor sites), hypercalcemia (in patients with bone metastases), and alopecia.
- Patients should be thoroughly educated on potential side effects and advised to report any concerning symptoms to their healthcare provider promptly.
Serious Warnings
- Black Box Warning: WARNING: SERIOUS AND LIFE-THREATENING EVENTS **Uterine Malignancies:** Tamoxifen is associated with an increased incidence of uterine malignancies, including endometrial cancer and uterine sarcoma. The risk of these events is increased with duration of treatment and dose, and is higher in postmenopausal women. Patients receiving tamoxifen should be regularly monitored for abnormal gynecological symptoms, such as vaginal bleeding, discharge, or pelvic pain or pressure. Prompt investigation of these symptoms is warranted to rule out malignancy. **Thromboembolic Events:** Tamoxifen increases the risk of life-threatening thromboembolic events, including deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke. This risk is particularly elevated in women receiving tamoxifen for breast cancer risk reduction (prevention) and for ductal carcinoma in situ (DCIS) following breast surgery and radiation. Physicians should carefully weigh the risks versus benefits before prescribing tamoxifen for these indications. Patients should be advised to seek immediate medical attention if they experience symptoms such as sudden onset of chest pain, shortness of breath, leg pain or swelling, or neurological symptoms suggestive of a stroke. The concurrent use of tamoxifen with coumarin-type anticoagulants is contraindicated for reduction in breast cancer incidence in high-risk women and for DCIS.
- Tamoxifen carries several significant warnings that necessitate careful patient evaluation and monitoring.
- It should be used with caution in patients with a history of thromboembolic events, as tamoxifen increases the risk of DVT, PE, and stroke.
- Patients with existing liver impairment may require dose adjustments and closer monitoring due to its hepatic metabolism.
- There is a risk of hypercalcemia, particularly in patients with bone metastases, which may require monitoring of serum calcium levels.
- Tamoxifen can cause ocular disturbances, including cataracts and retinopathy; therefore, regular ophthalmologic examinations are recommended.
- In premenopausal women, tamoxifen can suppress ovarian function, potentially leading to amenorrhea and infertility; effective non-hormonal contraception methods must be used during treatment and for two months following the last dose due to potential fetal harm (Category D).
- Concomitant use with potent CYP2D6 inhibitors (e.
- g.
- , paroxetine, fluoxetine) may reduce tamoxifen's active metabolite, endoxifen, potentially diminishing its efficacy.
- Careful consideration of drug interactions and patient-specific risk factors is essential before and during tamoxifen therapy.
How it Works (Mechanism of Action)
Tamoxifen functions as a selective estrogen receptor modulator (SERM). Its primary mechanism of action involves competitive binding to estrogen receptors (ER) in target tissues, particularly in breast cancer cells. In breast tissue, tamoxifen acts as an antagonist, preventing estrogen from binding to its receptors and thereby inhibiting estrogen-dependent cell growth and proliferation. This antagonistic effect is crucial for its therapeutic efficacy in ER-positive breast cancers. However, tamoxifen exhibits tissue-specific effects, acting as a partial agonist in other tissues such as bone, where it can contribute to beneficial effects on bone mineral density, and in the endometrium, where its agonistic activity can increase the risk of endometrial hyperplasia and cancer. Tamoxifen is extensively metabolized, primarily by cytochrome P450 enzymes (CYP3A4 and CYP2D6), to several active metabolites, including 4-hydroxytamoxifen and endoxifen, which possess significantly higher affinity for the estrogen receptor than the parent compound and contribute substantially to its anti-estrogenic effects. These metabolites play a critical role in its overall pharmacological activity.
Commercial Brands (Alternatives)
No other brands found for this formula.